Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Petter Bjornstad to Diabetes Mellitus, Type 2

This is a "connection" page, showing publications Petter Bjornstad has written about Diabetes Mellitus, Type 2.

 
Connection Strength
  
 
 
11.596
  
  1. Mottl AK, Sawinski DL, Bjornstad P. Kidney and Cardiovascular Protection in Diabetes: Beyond Diabetes Typology. Am J Kidney Dis. 2026 May; 87(5):730-739.
    View in: PubMed
    Score: 0.338
  2. Naik AS, Alakwaa FM, Nair V, McCown PJ, Schaub JA, Otto EA, Menon R, Annese F, Choi YJ, Hampson HE, Inge TH, Hartman J, Eddy S, Smith C, Hodgin JB, Inoki K, Srivastava SP, Al-Fagih K, Yoshida S, Goodrich JA, Cree MG, Narongkiatikhun P, Yuan L, Tommerdahl KL, Prasad P, van Raalte DH, Kelsey MM, Ryder JR, Dobbs TJ, Ladd P, Pennathur S, Nelson RG, Okabayashi Y, Puelles VG, Ferrence-Salo J, Beamish JA, Brosius FC, Nadeau KJ, Pyle L, Kretzler M, Bjornstad P. Metabolic surgery mitigates early kidney injury in obese youth with diabetes by suppressing mTORC1/JAK/STAT signaling. J Clin Invest. 2026 Apr 01; 136(7).
    View in: PubMed
    Score: 0.336
  3. Shapiro ALB, Narongkiatikhun P, Choi YJ, Wilkening G, Tommerdahl KL, Hamson HE, Pyle L, Bjornstad P. Altered brain function and structure in youth-onset type 2 diabetes. Eur J Endocrinol. 2025 Apr 30; 192(5):671-679.
    View in: PubMed
    Score: 0.319
  4. Platnick C, Choi YJ, Narongkiatikhun P, Bekelman N, Rountree-Jablin C, Birznieks C, Sell E, Tommerdahl KL, de Boer I, Shah VN, Nadeau KJ, Sawyer A, Pyle L, Bjornstad P. Relationships among biological sex, body composition, and bone mineral density in young persons with and without diabetes. J Pediatr Endocrinol Metab. 2025 May 26; 38(5):476-487.
    View in: PubMed
    Score: 0.318
  5. Bjornstad P, Arslanian SA, Hannon TS, Zeitler PS, Francis JL, Curtis AM, Turfanda I, Cox DA. Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study. Diabetes Care. 2024 09 01; 47(9):1617-1621.
    View in: PubMed
    Score: 0.305
  6. Narongkiatikhun P, Bjornstad P. Deciphering the kidney hemodynamic effects of SGLT2 inhibition: translating insights from rats to humans in type 2 diabetes. Kidney Int. 2024 09; 106(3):354-356.
    View in: PubMed
    Score: 0.305
  7. Bjornstad P, Choi YJ, Platnick C, Gross S, Narongkiatikhun P, Melena I, Remmers L, Baca M, Schutte G, Dobbs T, Vigers T, Pyle L, Driscoll L, Tommerdahl K, Kendrick J, Looker HC, Dart A, Cherney D, van Raalte DH, Srivastava A, Li L, Prasad P, Saulnier P, Nelson RG, Johnson RJ, Nadeau KJ. Insulin Secretion, Sensitivity, and Kidney Function in Young Individuals With Type 2 Diabetes. Diabetes Care. 2024 03 01; 47(3):409-417.
    View in: PubMed
    Score: 0.294
  8. Saulnier PJ, Looker HC, Layton A, Lemley KV, Nelson RG, Bjornstad P. Loss of Glomerular Permselectivity in Type 2 Diabetes Associates With Progression to Kidney Failure. Diabetes. 2023 11 01; 72(11):1682-1691.
    View in: PubMed
    Score: 0.288
  9. Saulnier PJ, Bjornstad P. Renal hemodynamic changes in patients with type 2 diabetes and their clinical impact. Presse Med. 2023 Mar; 52(1):104175.
    View in: PubMed
    Score: 0.286
  10. Sawyer A, Zeitler E, Trachtman H, Bjornstad P. Kidney Considerations in Pediatric Obesity. Curr Obes Rep. 2023 Sep; 12(3):332-344.
    View in: PubMed
    Score: 0.283
  11. Tommerdahl KL, Kula AJ, Bjornstad P. Pharmacological management of youth with type 2 diabetes and diabetic kidney disease: a comprehensive review of current treatments and future directions. Expert Opin Pharmacother. 2023 Jun; 24(8):913-924.
    View in: PubMed
    Score: 0.277
  12. Schaub JA, AlAkwaa FM, McCown PJ, Naik AS, Nair V, Eddy S, Menon R, Otto EA, Demeke D, Hartman J, Fermin D, O'Connor CL, Subramanian L, Bitzer M, Harned R, Ladd P, Pyle L, Pennathur S, Inoki K, Hodgin JB, Brosius FC, Nelson RG, Kretzler M, Bjornstad P. SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth-onset type 2 diabetes. J Clin Invest. 2023 03 01; 133(5).
    View in: PubMed
    Score: 0.275
  13. Tommerdahl KL, Kendrick J, Nelson RG, Bjornstad P. Youth versus adult-onset type 2 diabetic kidney disease: Insights into currently known structural differences and the potential underlying mechanisms. Clin Sci (Lond). 2022 11 11; 136(21):1471-1483.
    View in: PubMed
    Score: 0.269
  14. Bjornstad P, Chao LC, Cree-Green M, Dart AB, King M, Looker HC, Magliano DJ, Nadeau KJ, Pinhas-Hamiel O, Shah AS, van Raalte DH, Pavkov ME, Nelson RG. Youth-onset type 2 diabetes mellitus: an urgent challenge. Nat Rev Nephrol. 2023 03; 19(3):168-184.
    View in: PubMed
    Score: 0.268
  15. Tommerdahl KL, Kendrick J, Bjornstad P. The Role of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in the Prevention and Treatment of Diabetic Kidney Disease: Insights from the AMPLITUDE-O Trial. Clin J Am Soc Nephrol. 2022 06; 17(6):905-907.
    View in: PubMed
    Score: 0.258
  16. Tommerdahl KL, Nelson RG, Bjornstad P. Dapagliflozin in young people with type 2 diabetes. Lancet Diabetes Endocrinol. 2022 05; 10(5):303-304.
    View in: PubMed
    Score: 0.258
  17. Looker HC, Pyle L, Vigers T, Severn C, Saulnier PJ, Najafian B, Mauer M, Nelson RG, Bjornstad P. Structural Lesions on Kidney Biopsy in Youth-Onset and Adult-Onset Type 2 Diabetes. Diabetes Care. 2022 02 01; 45(2):436-443.
    View in: PubMed
    Score: 0.255
  18. Bjornstad P, Drews K, Zeitler PS. Long-Term Complications in Youth-Onset Type 2 Diabetes. Reply. N Engl J Med. 2021 11 18; 385(21):2016.
    View in: PubMed
    Score: 0.251
  19. Bjornstad P, Greasley PJ, Wheeler DC, Chertow GM, Langkilde AM, Heerspink HJL, Van Raalte DH. The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure. J Card Fail. 2021 12; 27(12):1447-1455.
    View in: PubMed
    Score: 0.245
  20. Saulnier PJ, Looker HC, Mauer M, Najafian B, Gand E, Ragot S, Nelson RG, Bjornstad P. Intraglomerular Dysfunction Predicts Kidney Failure in Type 2 Diabetes. Diabetes. 2021 10; 70(10):2344-2352.
    View in: PubMed
    Score: 0.245
  21. Tommerdahl KL, Nadeau KJ, Bjornstad P. Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists. Adv Chronic Kidney Dis. 2021 07; 28(4):337-346.
    View in: PubMed
    Score: 0.245
  22. Tommerdahl KL, Shapiro ALB, Nehus EJ, Bjornstad P. Early microvascular complications in type 1 and type 2 diabetes: recent developments and updates. Pediatr Nephrol. 2022 01; 37(1):79-93.
    View in: PubMed
    Score: 0.241
  23. Ryder JR, Xu P, Nadeau KJ, Kelsey MM, Xie C, Jenkins T, Inge TH, Bjornstad P. Effect of surgical versus medical therapy on estimated cardiovascular event risk among adolescents with type 2 diabetes and severe obesity. Surg Obes Relat Dis. 2021 Jan; 17(1):23-33.
    View in: PubMed
    Score: 0.231
  24. Bjornstad P, Nehus E, Jenkins T, Mitsnefes M, Moxey-Mims M, Dixon JB, Inge TH. Five-year kidney outcomes of bariatric surgery differ in severely obese adolescents and adults with and without type 2 diabetes. Kidney Int. 2020 05; 97(5):995-1005.
    View in: PubMed
    Score: 0.222
  25. Bjornstad P, Nehus E, van Raalte D. Bariatric surgery and kidney disease outcomes in severely obese youth. Semin Pediatr Surg. 2020 Feb; 29(1):150883.
    View in: PubMed
    Score: 0.221
  26. Bjornstad P, Nelson RG, Pavkov ME. Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes? Kidney Int. 2020 01; 97(1):31-33.
    View in: PubMed
    Score: 0.221
  27. Bjornstad P, Hughan K, Kelsey MM, Shah AS, Lynch J, Nehus E, Mitsnefes M, Jenkins T, Xu P, Xie C, Inge T, Nadeau K. Effect of Surgical Versus Medical Therapy on Diabetic Kidney Disease Over 5 Years in Severely Obese Adolescents With Type 2 Diabetes. Diabetes Care. 2020 01; 43(1):187-195.
    View in: PubMed
    Score: 0.218
  28. Bjornstad P, Laffel L, Lynch J, El Ghormli L, Weinstock RS, Tollefsen SE, Nadeau KJ. Elevated Serum Uric Acid Is Associated With Greater Risk for Hypertension and Diabetic Kidney Diseases in Obese Adolescents With Type 2 Diabetes: An Observational Analysis From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. Diabetes Care. 2019 06; 42(6):1120-1128.
    View in: PubMed
    Score: 0.210
  29. Bjornstad P, Cherney DZ. Renal Hyperfiltration in Adolescents with Type 2 Diabetes: Physiology, Sex Differences, and Implications for Diabetic Kidney Disease. Curr Diab Rep. 2018 03 19; 18(5):22.
    View in: PubMed
    Score: 0.195
  30. Bjornstad P, Nehus E, El Ghormli L, Bacha F, Libman IM, McKay S, Willi SM, Laffel L, Arslanian S, Nadeau KJ. Insulin Sensitivity and Diabetic Kidney Disease in Children and Adolescents With Type 2 Diabetes: An Observational Analysis of Data From the TODAY Clinical Trial. Am J Kidney Dis. 2018 01; 71(1):65-74.
    View in: PubMed
    Score: 0.190
  31. Bjornstad P, Truong U, Pyle L, Dorosz JL, Cree-Green M, Baumgartner A, Coe G, Regensteiner JG, Reusch JE, Nadeau KJ. Youth with type 1 diabetes have worse strain and less pronounced sex differences in early echocardiographic markers of diabetic cardiomyopathy compared to their normoglycemic peers: A RESistance to InSulin in Type 1 ANd Type 2 diabetes (RESISTANT) Study. J Diabetes Complications. 2016 08; 30(6):1103-10.
    View in: PubMed
    Score: 0.170
  32. Bjornstad P, Truong U, Dorosz JL, Cree-Green M, Baumgartner A, Coe G, Pyle L, Regensteiner JG, Reusch JE, Nadeau KJ. Cardiopulmonary Dysfunction and Adiponectin in Adolescents With Type 2 Diabetes. J Am Heart Assoc. 2016 Mar 18; 5(3):e002804.
    View in: PubMed
    Score: 0.170
  33. Bjornstad P, Cherney DZ, Maahs DM, Nadeau KJ. Diabetic Kidney Disease in Adolescents With Type 2 Diabetes: New Insights and Potential Therapies. Curr Diab Rep. 2016 Feb; 16(2):11.
    View in: PubMed
    Score: 0.168
  34. Bjornstad P, Maahs DM, Cherney DZ, Cree-Green M, West A, Pyle L, Nadeau KJ. Insulin sensitivity is an important determinant of renal health in adolescents with type 2 diabetes. Diabetes Care. 2014 Nov; 37(11):3033-9.
    View in: PubMed
    Score: 0.151
  35. van Baar MJB, Bjornstad P, Touw DJ, Joles JA, Krebber MM, Cherney DZI, van Raalte DH, Muskiet MHA. Renal functional reserve predicts GFR response to empagliflozin in RENALIS and RACELINES clinical trials. Nephrol Dial Transplant. 2026 Jul 31; 41(8):1520-1528.
    View in: PubMed
    Score: 0.087
  36. Athinarayanan SJ, Bjornstad P, Shanmugam PV, Weimbs T, Wolfberg AJ, Volek JS, Himmelfarb J, Johnson RJ. Effectiveness of Telehealth Low-Carbohydrate Intervention in Preventing Chronic Kidney Disease: A Real-World, Retrospective, Matched Cohort Study. Diabetes Obes Metab. 2026 10; 28(10):9054-9068.
    View in: PubMed
    Score: 0.087
  37. Liu JJ, Liu S, de Keizer J, Zheng H, Lee J, Javaugue V, Gurung RL, Ang K, Potier L, Nelson RG, Kestenbaum B, Bjornstad P, Lim SC, Hadjadj S, Saulnier PJ. Fasting urine osmolality and risk of kidney disease progression in patients with type 2 diabetes. Nephrol Dial Transplant. 2026 Jun 30; 41(7):1304-1312.
    View in: PubMed
    Score: 0.086
  38. Heerspink HJL, van Raalte DH, Bjornstad P, Bunck MC, Wu P, Tunali I, Milicevic Z, Koeneman L. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Nephrol Dial Transplant. 2026 May 29; 41(6):1058-1068.
    View in: PubMed
    Score: 0.086
  39. van Heugten MH, Beckmann SB, Salib M, Curovic VR, Beernink JM, Faivre A, Laverman GD, Wu Q, Bjornstad P, Hall AM, Rossing P, Fenton RA, Heerspink HJL, Hoorn EJ. Distinct proteomic signatures of urinary extracellular vesicles link to albuminuria and treatment responses in diabetic kidney disease. Kidney Int. 2026 Aug; 110(2):438-450.
    View in: PubMed
    Score: 0.086
  40. Nair V, Minakawa A, Smith C, Berthier CC, Hartman J, Menon R, Fermin D, Otto EA, Gisch DL, Eadon MT, Jain S, Choi YJ, Pyle L, Eichinger F, Alakwaa FM, Rose MP, Subramanian L, El Saghir J, Beamish JA, Hodgin JB, Brosius FC, Bjornstad P, Nelson PJ, Harder JL, Werner T, Kretzler M, Schaub JA. Hypoxia inducible factor network reflects kidney disease progression in diabetes and sodium-glucose co-transporters inhibition. Signal Transduct Target Ther. 2026 Apr 21; 11(1).
    View in: PubMed
    Score: 0.085
  41. Moedt E, Koshino A, Jongs N, Ju W, Nair V, Kretzler M, Hansen MK, Arnott CG, Wheeler DC, Rossing P, Coca SG, Hammarstedt A, Greasley PJ, Bjornstad P, Bakker SJL, Heerspink HJL. Association of Urinary EGF with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 Inhibition. J Am Soc Nephrol. 2026 Oct 01; 37(10):2210-2220.
    View in: PubMed
    Score: 0.085
  42. Dobbs TJ, Pyle L, Moore JM, Garrish J, Behn CD, Weissenkampen D, Baumgartner AD, Gross S, Schutte G, Birznieks C, Melena I, Remmers L, Driscoll L, Cree MG, Kelsey MM, Shah AS, Inge TH, Bjornstad P, Nadeau KJ. Impact of Vertical Sleeve Gastrectomy in Youth-Onset Type 2 Diabetes: Changes in Glycemia, Insulin Sensitivity, and Secretion. Obesity (Silver Spring). 2026 Jun; 34 Suppl 1:121-133.
    View in: PubMed
    Score: 0.084
  43. Kwok R, Kishore K, Zafari T, Koye DN, Hachem M, de Boer IH, Jeong TD, Min WK, Porrini E, Bjornstad P, Tham YC, MacIsaac RJ, Churilov L, Ekinci EI. RenoTrue: A diabetes-specific machine learning model to estimate glomerular filtration rate for people with diabetes. Diabetes Res Clin Pract. 2026 Mar; 233:113137.
    View in: PubMed
    Score: 0.084
  44. Dobbs TJ, Gutierrez L, Hu HH, Hunter KS, Fonseca B, Browne L, Winter D, Cree MG, Pyle L, Hills-Dunlap JL, Reusch JEB, Kelsey MM, Inge TH, Bjornstad P, Nadeau KJ. MRI Analysis of Cardiac Fat, Abdominal Adiposity and Cardiac Function After Vertical Sleeve Gastrectomy in Youth With Type 2 Diabetes. Pediatr Obes. 2026 Jan; 21(1):e70068.
    View in: PubMed
    Score: 0.083
  45. Pruijm M, Belmar N, Bjornstad P, Cherney DZI, Das V, Gunnarsson T, Hodgin JB, Schytz PA, Tuttle KR, Kretzler M. REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide. Kidney Int. 2026 01; 109(1):6-16.
    View in: PubMed
    Score: 0.083
  46. Cherney DZI, Belmar N, Bjornstad P, Chacko MM, Gunnarsson TP, Hodgin JB, Kretzler M, Pruijm M, Schytz PA, Tuttle KR. Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2025 Oct 30; 40(11):2182-2192.
    View in: PubMed
    Score: 0.083
  47. Beernink JM, Jongs N, Mosterd CM, Scholtes RA, Caldwell-McGee A, Casillas D, Driscoll L, Greasley PJ, Karlsson C, Hammarstedt A, Sridhar VS, Muskiet MHA, Laverman GD, Cherney DZI, Bjornstad P, van Raalte DH, Heerspink HJL. Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial. Diabetes Obes Metab. 2025 08; 27(8):4415-4426.
    View in: PubMed
    Score: 0.080
  48. van Baar MJB, Muskiet MHA, Scholtes RA, Touw DJ, Nieuwdorp M, Kramer MHH, Joles JA, Cherney DZI, Bjornstad P, Krebber MM, van Raalte DH. Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial. Diabetes Obes Metab. 2025 07; 27(7):3943-3956.
    View in: PubMed
    Score: 0.080
  49. Kwok R, Kishore K, Zafari T, Koye DN, Hachem M, de Boer IH, Jeong TD, Min WK, Porrini E, Bjornstad P, MacIsaac RJ, Churilov L, Ekinci EI. Comparative performance of CKD-EPI equations in people with diabetes: An international pooled analysis of individual participant data. Diabetes Res Clin Pract. 2025 May; 223:112104.
    View in: PubMed
    Score: 0.079
  50. Keller F, Denicolò S, Leierer J, Kruus M, Heinzel A, Kammer M, Ju W, Nair V, Burdet F, Ibberson M, Menon R, Otto E, Choi YJ, Pyle L, Ladd P, Bjornstad PM, Eder S, Rosivall L, Mark PB, Wiecek A, Heerspink HJL, Kretzler M, Oberbauer R, Mayer G, Perco P. Association of Urinary Epidermal Growth Factor, Fatty Acid-Binding Protein 3, and Vascular Cell Adhesion Molecule 1 Levels with the Progression of Early Diabetic Kidney Disease. Kidney Blood Press Res. 2024; 49(1):1013-1025.
    View in: PubMed
    Score: 0.077
  51. Chen ZZ, Lu C, Dreyfuss JM, Tiwari G, Shi X, Zheng S, Wolfs D, Pyle L, Bjornstad P, El Ghormli L, Gerszten RE, Isganaitis E. Circulating Metabolite Biomarkers of Glycemic Control in Youth-Onset Type 2 Diabetes. Diabetes Care. 2024 09 01; 47(9):1597-1607.
    View in: PubMed
    Score: 0.076
  52. Kugathasan L, Sridhar VS, Tommerdahl KL, Xu C, Bjornstad P, Advani A, Cherney DZI. Minireview: Understanding and targeting inflammatory, hemodynamic and injury markers for cardiorenal protection in type 1 diabetes. Metabolism. 2024 04; 153:155785.
    View in: PubMed
    Score: 0.073
  53. Sharma K, Zhang G, Hansen J, Bjornstad P, Lee HJ, Menon R, Hejazi L, Liu JJ, Franzone A, Looker HC, Choi BY, Fernandez R, Venkatachalam MA, Kugathasan L, Sridhar VS, Natarajan L, Zhang J, Sharma VS, Kwan B, Waikar SS, Himmelfarb J, Tuttle KR, Kestenbaum B, Fuhrer T, Feldman HI, de Boer IH, Tucci FC, Sedor J, Heerspink HL, Schaub J, Otto EA, Hodgin JB, Kretzler M, Anderton CR, Alexandrov T, Cherney D, Lim SC, Nelson RG, Gelfond J, Iyengar R. Endogenous adenine mediates kidney injury in diabetic models and predicts diabetic kidney disease in patients. J Clin Invest. 2023 10 16; 133(20).
    View in: PubMed
    Score: 0.072
  54. Sen T, Ju W, Nair V, Ladd P, Menon R, Otto EA, Pyle L, Vigers T, Nelson RG, Arnott C, Neal B, Hansen MK, Kretzler M, Bjornstad P, Heerspink HJL. Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes. Kidney Int. 2023 10; 104(4):828-839.
    View in: PubMed
    Score: 0.071
  55. Scarr D, Lovblom LE, Bjornstad P, Perkins BA, Kugathasan L, Cherney DZI, Lovshin JA. Estimated glomerular filtration rate calculated by serum creatinine lacks precision and accuracy in adults with type 2 diabetes with preserved renal function. J Diabetes Complications. 2023 09; 37(9):108562.
    View in: PubMed
    Score: 0.071
  56. El Ghormli L, Wen H, Uschner D, Haymond MW, Hughan KS, Kutney K, Laffel L, Tollefsen SE, Escaname EN, Lynch J, Bjornstad P. Trajectories of eGFR and risk of albuminuria in youth with type 2 diabetes: results from the TODAY cohort study. Pediatr Nephrol. 2023 12; 38(12):4137-4144.
    View in: PubMed
    Score: 0.070
  57. Stefansson VTN, Nair V, Melsom T, Looker HC, Mariani LH, Fermin D, Eichinger F, Menon R, Subramanian L, Ladd P, Harned R, Harder JL, Hodgin JB, Bjornstad P, Nelson PJ, Eriksen BO, Nelson RG, Kretzler M. Molecular programs associated with glomerular hyperfiltration in early diabetic kidney disease. Kidney Int. 2022 12; 102(6):1345-1358.
    View in: PubMed
    Score: 0.066
  58. Sen T, Scholtes R, Greasley PJ, Cherney DZI, Dekkers CCJ, Vervloet M, Danser AHJ, Barbour SJ, Karlsson C, Hammarstedt A, Li Q, Laverman GD, Bjornstad P, van Raalte DH, Heerspink HJL. Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND. Diabetes Obes Metab. 2022 08; 24(8):1578-1587.
    View in: PubMed
    Score: 0.065
  59. Suijk DLS, van Baar MJB, van Bommel EJM, Iqbal Z, Krebber MM, Vallon V, Touw D, Hoorn EJ, Nieuwdorp M, Kramer MMH, Joles JA, Bjornstad P, van Raalte DH. SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function. Clin J Am Soc Nephrol. 2022 05; 17(5):663-671.
    View in: PubMed
    Score: 0.064
  60. Hesp AC, Smits MM, van Bommel EJM, Muskiet MHA, Tonneijck L, Nieuwdorp M, Kramer MHH, Joles JA, Bjornstad P, van Raalte DH. Kidney hemodynamic profile and systemic vascular function in adults with type 2 diabetes: Analysis of three clinical trials. J Diabetes Complications. 2022 03; 36(3):108127.
    View in: PubMed
    Score: 0.063
  61. Bjornstad P, Drews KL, Caprio S, Gubitosi-Klug R, Nathan DM, Tesfaldet B, Tryggestad J, White NH, Zeitler P. Long-Term Complications in Youth-Onset Type 2 Diabetes. N Engl J Med. 2021 07 29; 385(5):416-426.
    View in: PubMed
    Score: 0.061
  62. van Velzen DM, Smits MM, van Bommel EJM, Muskiet MHA, Tonneijck L, Kramer MHH, Joles JA, den Heijer M, Nokoff N, Bjornstad P, van Raalte DH. Kidney hemodynamic function in men and postmenopausal women with type 2 diabetes and preserved kidney function. Am J Physiol Renal Physiol. 2021 06 01; 320(6):F1152-F1158.
    View in: PubMed
    Score: 0.060
  63. van Raalte DH, Bjornstad P, Heerspink HJL, Persson F, Cherney DZI. Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies. Kidney Int. 2021 03; 99(3):768-770.
    View in: PubMed
    Score: 0.060
  64. Tommerdahl KL, Baumgartner K, Schäfer M, Bjornstad P, Melena I, Hegemann S, Baumgartner AD, Pyle L, Cree-Green M, Truong U, Browne L, Regensteiner JG, Reusch JEB, Nadeau KJ. Impact of Obesity on Measures of Cardiovascular and Kidney Health in Youth With Type 1 Diabetes as Compared With Youth With Type 2 Diabetes. Diabetes Care. 2021 03; 44(3):795-803.
    View in: PubMed
    Score: 0.059
  65. Scholtes RA, van Baar MJB, Kok MD, Bjornstad P, Cherney DZI, Joles JA, van Raalte DH. Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors. Nephrology (Carlton). 2021 May; 26(5):377-390.
    View in: PubMed
    Score: 0.059
  66. Mosterd CM, Bjornstad P, van Raalte DH. Nephroprotective effects of GLP-1 receptor agonists: where do we stand? J Nephrol. 2020 Oct; 33(5):965-975.
    View in: PubMed
    Score: 0.056
  67. Hesp AC, Schaub JA, Prasad PV, Vallon V, Laverman GD, Bjornstad P, van Raalte DH. The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors? Kidney Int. 2020 09; 98(3):579-589.
    View in: PubMed
    Score: 0.056
  68. van Bommel EJM, Ruiter D, Muskiet MHA, van Baar MJB, Kramer MHH, Nieuwdorp M, Joles JA, Bjornstad P, van Raalte DH. Insulin Sensitivity and Renal Hemodynamic Function in Metformin-Treated Adults With Type 2 Diabetes and Preserved Renal Function. Diabetes Care. 2020 01; 43(1):228-234.
    View in: PubMed
    Score: 0.054
  69. Potier L, Roussel R, Marre M, Bjornstad P, Cherney DZ, El Boustany R, Fumeron F, Venteclef N, Gautier JF, Hadjadj S, Mohammedi K, Velho G. Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes. Diabetes Care. 2019 12; 42(12):2290-2297.
    View in: PubMed
    Score: 0.054
  70. Al-Ozairi E, Rivard CJ, Sanchez Lozada LG, Lanaspa MA, Bjornstad P, Al Salem D, Alhubail A, Megahed A, Kuwabara M, Johnson RJ, Asad RA. Fructose tolerance test in obese people with and without type 2 diabetes. J Diabetes. 2020 Mar; 12(3):197-204.
    View in: PubMed
    Score: 0.054
  71. Scholtes RA, van Baar MJB, Lytvyn Y, Bjornstad P, Nieuwdorp M, Cherney DZI, van Raalte DH. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both? Diabetes Obes Metab. 2019 04; 21 Suppl 2:24-33.
    View in: PubMed
    Score: 0.052
  72. Bjornstad P, Eckel RH. Pathogenesis of Lipid Disorders in Insulin Resistance: a Brief Review. Curr Diab Rep. 2018 10 17; 18(12):127.
    View in: PubMed
    Score: 0.051
  73. León Jiménez D, Cherney DZI, Bjornstad P, Castilla-Guerra L, Miramontes González JP. Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease. Am J Physiol Renal Physiol. 2018 11 01; 315(5):F1406-F1415.
    View in: PubMed
    Score: 0.050
  74. Tonneijck L, Muskiet MHA, Smits MM, Bjornstad P, Kramer MHH, Diamant M, Hoorn EJ, Joles JA, van Raalte DH. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials. Diabetes Obes Metab. 2018 05; 20(5):1235-1245.
    View in: PubMed
    Score: 0.048
  75. Gidding SS, Bacha F, Bjornstad P, Levitt Katz LE, Levitsky LL, Lynch J, Tryggestad JB, Weinstock RS, El Ghormli L, Lima JAC. Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study. J Pediatr. 2018 01; 192:86-92.e5.
    View in: PubMed
    Score: 0.048
  76. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation. 2017 Oct 24; 136(17):1643-1658.
    View in: PubMed
    Score: 0.047
  77. Shah P, Bjornstad P, Johnson RJ. Hyperuricemia as a potential risk factor for type 2 diabetes and diabetic nephropathy. J Bras Nefrol. 2016 Dec; 38(4):386-387.
    View in: PubMed
    Score: 0.045
  78. Bjornstad P, Lanaspa MA, Ishimoto T, Kosugi T, Kume S, Jalal D, Maahs DM, Snell-Bergeon JK, Johnson RJ, Nakagawa T. Fructose and uric acid in diabetic nephropathy. Diabetologia. 2015 Sep; 58(9):1993-2002.
    View in: PubMed
    Score: 0.040
  79. Kelsey MM, Bjornstad P, McFann K, Nadeau K. Testosterone concentration and insulin sensitivity in young men with type 1 and type 2 diabetes. Pediatr Diabetes. 2016 May; 17(3):184-90.
    View in: PubMed
    Score: 0.039
  80. Bergmann KR, Bjornstad P, Abuzzahab MJ, Zhong L, Collins-Dippel E, Nickel A, Watson D, Kharbanda A. Multicentre, retrospective cohort study protocol to identify racial and ethnic differences in acute kidney injuries in children and adolescents with diabetic ketoacidosis. BMJ Open. 2024 06 05; 14(6):e086261.
    View in: PubMed
    Score: 0.019
  81. van Raalte DH, Bjornstad P, Cherney DZI, de Boer IH, Fioretto P, Gordin D, Persson F, Rosas SE, Rossing P, Schaub JA, Tuttle K, Waikar SS, Heerspink HJL. Combination therapy for kidney disease in people with diabetes mellitus. Nat Rev Nephrol. 2024 07; 20(7):433-446.
    View in: PubMed
    Score: 0.019
  82. Kelsey MM, Zaepfel A, Bjornstad P, Nadeau KJ. Age-related consequences of childhood obesity. Gerontology. 2014; 60(3):222-8.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)